Tempest Therapeutics, Inc. (TPST): Form 8-K filed 2026-09-28
- Accepted by EDGAR
- 2026-09-28 16:05 ET
- Event date
- 2026-09-22
- Accession no.
- 0001213900-26-104034
- Original filing
- SEC EDGAR filing index
Items reported
- Item 1.01: Entry into a Material Definitive Agreement
The company signed a material agreement outside the ordinary course of business, or materially amended one. Typical examples are credit agreements, merger agreements, large supply or licensing contracts and financing arrangements. - Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
A director or a named officer (such as the CEO or CFO) left or was appointed, or certain executive compensation arrangements were adopted or changed. - Item 7.01: Regulation FD Disclosure
The company is making information public under Regulation FD, which requires broad public disclosure of material information shared with certain market participants. Investor presentations and press releases are common. Like Item 2.02, this information is generally "furnished" rather than "filed". - Item 9.01: Financial Statements and Exhibits
Lists the financial statements, pro forma information and exhibits filed with the report. It almost always accompanies another Item and is rarely news on its own.
Documents
| Type | Description | Document |
|---|---|---|
| 8-K | CURRENT REPORT | ea0306741-8k_tempest.htm |
| EX-10.1 | MASTER SERVICES AGREEMENT, DATED SEPTEMBER 22, 2026, BETWEEN FACTOR BIOSCIENCE I | ea030674101ex10-1.htm |
| EX-99.1 | PRESS RELEASE, DATED SEPTEMBER 23, 2026, FURNISHED HEREWITH | ea030674101ex99-1.htm |
This page lists what the filing reports; it does not summarize or interpret it. Read the original documents on SEC EDGAR. How to read an 8-K.